<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6248">
  <stage>Registered</stage>
  <submitdate>8/09/2016</submitdate>
  <approvaldate>8/09/2016</approvaldate>
  <nctid>NCT02898454</nctid>
  <trial_identification>
    <studytitle>Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps</studytitle>
    <scientifictitle>A Randomized, Double-blind, 52-week, Placebo Controlled Efficacy and Safety Study of Dupilumab, in Patients With Bilateral Nasal Polyposis on a Background Therapy With Intranasal Corticosteroids</scientifictitle>
    <utrn />
    <trialacronym>SINUS-52</trialacronym>
    <secondaryid>2015-001314-10</secondaryid>
    <secondaryid>EFC14280</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Nasal Polyps</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Dupilumab SAR231893 (REGN668)
Treatment: drugs - Placebo
Treatment: drugs - Mometasone furoate nasal spray

Experimental: Dupilumab (Arm A) - A dose of dupilumab will be administered subcutaneously (SC) every 2 weeks (q2w) until Week 52. Patients will use MFNS daily.

Experimental: Dupilumab (Arm B) - A dose of dupilumab will be administered SC every 2 weeks until Week 24, then every 4 weeks (q4w) until Week 52. Patients will use MFNS daily.

Placebo Comparator: Placebo (Arm C) - A matching placebo will be administered SC every 2 weeks (q2w) until Week 52. Patients will use MFNS daily.


Treatment: drugs: Dupilumab SAR231893 (REGN668)
Pharmaceutical form: Solution
Route of administration: Subcutaneous

Treatment: drugs: Placebo
Pharmaceutical form: Solution
Route of administration: Subcutaneous

Treatment: drugs: Mometasone furoate nasal spray
Pharmaceutical form: Suspension
Route of administration: Intranasal

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change from baseline in nasal congestion/obstruction (NC) symptom severity score based on the patient daily morning assessment</outcome>
      <timepoint>From baseline to Week 24</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change from baseline in nasal polyposis score (NPS) as assessed by nasal endoscopy</outcome>
      <timepoint>From baseline to Week 24</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change from baseline in sinus opacifications as assessed by CT scans using Lund Mackay Score (For Japan only)</outcome>
      <timepoint>From baseline to Week 24</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in TSS</outcome>
      <timepoint>From baseline to Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in University of Pennsylvania Smell Identification Test</outcome>
      <timepoint>From baseline to Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in severity of decreased/ loss of smell as assessed by the patient</outcome>
      <timepoint>From baseline to Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in sinus opacifications as assessed by CT scans using Lund Mackay Score (This endpoint will not be assessed as a secondary endpoint for Japan as it is already a co-primary endpoint).</outcome>
      <timepoint>From baseline to Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in in sinonasal outcome test-22 (SNOT-22)</outcome>
      <timepoint>From baseline to Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of patients during study treatment receiving systemic corticosteroid for NP and/or planned to under surgery for nasal polyps</outcome>
      <timepoint>52 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in NC for every two weeks (q2w) (Arm A) versus placebo (Arm C)</outcome>
      <timepoint>From baseline to Week 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in NPS for q2w (Arm A) versus placebo (Arm C)</outcome>
      <timepoint>From baseline to Week 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in NC for q2w/q4w (Arm B) versus placebo (Arm C)</outcome>
      <timepoint>From baseline to Week 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in NPS for q2w/q4w (Arm B) versus placebo (Arm C)</outcome>
      <timepoint>From baseline to Week 52</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion criteria :

          -  Patients with bilateral sinonasal polyposis that despite prior treatment with systemic
             corticosteroids (SCS) anytime within the past 2 years; and/or have a medical
             contraindication/intolerance to SCS; and/or had prior surgery for NP at the screening
             visit, have:

          -  An endoscopic bilateral NPS of at least 5 out of a maximum score of 8 (with a minimum
             score of 2 in each nasal cavity).

          -  Ongoing symptoms (for at least 8 weeks before V1) of nasal congestion/
             blockage/obstruction with moderate or severe symptom severity (score 2 or 3) at V1 and
             a weekly average severity of greater than 1 at time of randomization (V2), and another
             symptom such as loss of smell, rhinorrhea (anterior/posterior).

          -  Signed written informed consent.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria:

          -  Patients &lt;18 years of age.

          -  Patient who has been previously treated in dupilumab studies.

          -  Patient who has taken:

          -  Biologic therapy/ systemic immunosuppressant to treat inflammatory disease or
             autoimmune disease (eg, rheumatoid arthritis, inflammatory bowel disease, primary
             biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis, etc.) within 2
             months before V1 or 5 half-lives, whichever is longer.

          -  Any experimental monoclonal antibody (mAB) within 5 half-lives or within 6 months
             before V1 if the half-life is unknown.

          -  Anti-immunoglobulin E therapy (omalizumab) within 130 days prior to V1.

          -  Patients who are receiving leukotriene antagonists/modifiers at V1 unless they are on
             a continuous treatment for at least 30 days prior to V1.

          -  Initiation of allergen immunotherapy within 3 months prior to V1 or a plan to begin
             therapy or change its dose during the run-in period or the randomized treatment
             period.

          -  Patients who have undergone any intranasal and/or sinus surgery (including
             polypectomy) within 6 months before V1.

          -  Patients who have had a sinonasal or sinus surgery changing the lateral wall structure
             of the nose making impossible the evaluation of NPS.

          -  Patients with conditions/concomitant diseases making them non evaluable at V1 or for
             the primary efficacy endpoint such as:

          -  Antrochoanal polyps,

          -  Nasal septal deviation that would occlude at least one nostril,

          -  Acute sinusitis, nasal infection or upper respiratory infection,

          -  Ongoing rhinitis medicamentosa,

          -  Allergic granulomatous angiitis (Churg-Strauss syndrome), granulomatosis with
             polyangiitis (Wegener's granulomatosis),Young's syndrome, Kartagener's syndrome or
             other dyskinetic ciliary syndromes, concomitant cystic fibrosis,

          -  Radiologic suspicion, or confirmed invasive or expansive fungal rhinosinusitis.

          -  Patients with nasal cavity malignant tumor and benign tumors (eg, papilloma, blood
             boil etc.).

          -  Patients with forced expiratory volume (FEV1) 50% or less (of predicted normal).

          -  Patients receiving concomitant treatment prohibited in the study.

          -  Treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit.

          -  History of human immunodeficiency virus (HIV) infection or positive HIV serology at
             screening.

          -  Positive with hepatitis B surface antigen (HBsAg) or hepatitis C antibody at the
             screening visit.

          -  Active chronic or acute infection requiring systemic treatment within 2 weeks before
             the baseline visit.

          -  Known or suspected history of immunosuppression.

          -  Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed
             during the study.

          -  Women unwilling to use adequate birth control, if of reproductive potential and
             sexually active.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>360</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>19/11/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Investigational Site Number 0360002 - Clayton</hospital>
    <hospital>Investigational Site Number 0360004 - Herston</hospital>
    <hospital>Investigational Site Number 0360005 - Murdoch</hospital>
    <hospital>Investigational Site Number 0360001 - Parkville</hospital>
    <hospital>Investigational Site Number 0360003 - Prahran</hospital>
    <postcode>3168 - Clayton</postcode>
    <postcode>4029 - Herston</postcode>
    <postcode>6150 - Murdoch</postcode>
    <postcode>3050 - Parkville</postcode>
    <postcode>3004 - Prahran</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Caba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Mendoza</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Rosario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>San Miguel De Tucumán</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruxelles</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Gent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Kingston</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Montreal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ottawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Trois-Rivieres</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Vancouver</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Quillota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>San Fernando</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Santiago</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Talca</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Viña Del Mar</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Hadera</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Nahariya</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Petah-Tikva</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Rehovot</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Tel Hashomer</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Bunkyo-Ku</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Chiyoda-Ku</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Fukuoka-Shi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Hirakata-Shi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Hiroshima-Shi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Iida-Shi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Inzai-Shi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Itabashi-Ku</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Izumisano-Shi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Kawasaki-Shi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Kitakyushu-Shi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Kumamoto-Shi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Kyoto-Shi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Meguro-Ku</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Minato-Ku</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Moriguchi-Shi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Okayama-Shi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Osaka-Shi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Ota-Ku</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Sendai-Shi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Shimonoseki-Shi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Shinagawa-Ku</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Shinjyuku-Ku</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Takatsuki-Shi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Yoshida-Gun</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Chihuahua</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Durango</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Guadalajara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Monterrey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Aveiro</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Guimarães</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Lisboa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Matosinhos</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Porto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Viana Do Castelo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Odintsovo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Saint-Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Stavropol</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Yaroslavl</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Jerez De La Frontera</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Sevilla</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Lund</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Stockholm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Ankara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Bursa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Istanbul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Izmir</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Rize</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Sanofi</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Regeneron Pharmaceuticals</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Primary Objective:

      To evaluate the efficacy of dupilumab compared to placebo on a background of mometasone
      furoate nasal spray (MFNS) in reducing nasal congestion/obstruction (NC) severity and
      endoscopic nasal polyposis score (NPS) in patients with bilateral nasal polyposis (NP). In
      addition for Japan, reduction in computed tomography (CT) scan opacification of the sinuses
      will be also a co-primary objective.

      Secondary Objectives:

        -  To evaluate the efficacy of dupilumab in improving total symptoms score (TSS).

        -  To evaluate the efficacy of dupilumab in improving sense of smell.

        -  To evaluate the efficacy of dupilumab in reducing CT scan opacification of the sinuses
           (Primary objective for Japan).

        -  To evaluate ability of dupilumab in reducing proportion of patients requiring treatment
           with oral corticosteroids or NP surgery.

        -  To evaluate the effect of dupilumab on patient reported outcomes and health related
           quality of life outcome by sinonasal outcome test-22 (SNOT-22).

        -  To evaluate efficacy with various regimen.

        -  To evaluate the effect of dupilumab in the subgroups of patients with prior surgery and
           co-morbid asthma (including non-steroid antiinflammatory drug [NSAID] exacerbated
           respiratory disease [NERD]).

        -  To evaluate the safety of dupilumab in patients with bilateral NP.

        -  To evaluate functional dupilumab concentrations (systemic exposure) and incidence of
           treatment-emergent anti-drug antibodies (ADA).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02898454</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Sciences &amp; Operations</name>
      <address>Sanofi</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>For site information, send an email with site number to</name>
      <address />
      <phone />
      <fax />
      <email>Contact-Us@sanofi.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>